Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Analysts at SunTrust Banks issued their FY2023 earnings per share (EPS) estimates for Nabriva Therapeutics in a research report issued on Wednesday, March 13th. SunTrust Banks analyst E. Nash forecasts that the biotechnology company will earn $0.58 per share for the year.
NBRV has been the topic of several other reports. Zacks Investment Research upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Tuesday, February 5th. Northland Securities reiterated a “buy” rating and issued a $12.50 price objective on shares of Nabriva Therapeutics in a research note on Tuesday. BidaskClub upgraded Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Nabriva Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Nabriva Therapeutics presently has a consensus rating of “Buy” and an average target price of $10.22.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBRV. Jane Street Group LLC bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $29,000. HRT Financial LLC bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $31,000. Two Sigma Advisers LP bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $37,000. Paloma Partners Management Co bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $54,000. Finally, Wedbush Securities Inc. grew its position in Nabriva Therapeutics by 12.5% during the 4th quarter. Wedbush Securities Inc. now owns 103,550 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 11,500 shares during the last quarter. Institutional investors and hedge funds own 4.81% of the company’s stock.
In other Nabriva Therapeutics news, Director Charles A. Rowland, Jr. purchased 53,000 shares of the firm’s stock in a transaction that occurred on Monday, December 24th. The shares were acquired at an average cost of $1.31 per share, for a total transaction of $69,430.00. Following the transaction, the director now directly owns 53,000 shares in the company, valued at $69,430. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.15% of the stock is owned by corporate insiders.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
See Also: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.